Abstracts tagged "Autoinflammatory Disease"

Abstract Number: 772 • 2019 ACR/ARP Annual Meeting
The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Shoko Tsuji¹, Hidenori Matsuzaki ², Masanori Iseki ³, Akiko Nagasu ¹, Hiroyasu Hirano ¹, Katsuhiko Ishihara ⁴, Naoyasu Ueda ⁵, Yoshitaka Honda ⁶, Takahiko Horiuchi ⁷, Ryuta Nishikomori ⁸, Yoshitaka Morita ¹ and Tomoyuki Mukai ⁹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, shobara, Hiroshima, Japan, ³Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Immunology and Molecular Genetics, Kurashiki, Okayama, Japan, ⁵Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, ⁶Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁸Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, Japan, ⁹Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan
Background/Purpose: TNF Receptor-Associated Periodic Syndrome (TRAPS) is one of the autoinflammatory diseases. TRAPS is caused by heterozygous mutations in the TNFRSF1A gene. Although more than…
Abstract Number: 799 • 2019 ACR/ARP Annual Meeting
Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital
Mireia Lopez-corbeto¹ and Estefania Moreno Ruzafa ¹, ¹Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Autoinflammatory diseases (AIDs) cause chronic systemic inflammation that can damage multiple organs. Recently, the ADDI index has been developed and validated in the four…
Abstract Number: 810 • 2019 ACR/ARP Annual Meeting
Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase
Adriana de Jesus¹, Gina Montealegre Sanchez ², Helen Freeman ³, Neil Martin ⁴, Ebun Omoyinmi ⁵, Katherine Calvo ⁶, Richard Chyi-chia Lee ⁷, Murray Passo ⁸, Natasha Ruth ⁸, David Kleiner ⁷, Yan Huang ⁹, Nirali Shah ¹⁰, Paul Brogan ¹¹, SuJin Hwang ¹², HyeSun Kuehn ¹², Sergio Rosenzweig ¹², Zuoming Deng ¹³, Anna Huttenlocher ¹⁴, Susan Moir ¹⁵, Douglas Kuhns ¹⁶ and Raphaela Goldbach-Mansky ¹⁷, ¹Translation Autoinflammatory Diseases Section/NIAID/NIH, Silver Spring, MD, ²Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ³Raigmore Hospital, Inverness, United Kingdom, ⁴Royal Hospital for Children, Glasgow, United Kingdom, ⁵University College London Institute of Child Health, London, United Kingdom, ⁶Hematology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, ⁷Laboratory of Pathology/NCI/NIH, Bethesda, MD, ⁸Medical University of South Carolina, Charleston, SC, ⁹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, MD, ¹⁰Pediatric Oncology Branch/NCI/NIH, Bethesda, MD, ¹¹Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ¹²Immunology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, ¹³Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹⁴Department of Pediatrics/University of Wisconsin, Madison, WI, ¹⁵Immunopathogenesis Section/NIAID/NIH, Bethesda, MD, ¹⁶Collaborative Clinical Research Branch/NIAID/NIH, Bethesda, MD, ¹⁷Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD
Background/Purpose: Lyn kinase is a member of the Src family of non-receptor tyrosine-protein kinases that modifies signals from various cell surface receptors and regulates innate…
Abstract Number: 903 • 2019 ACR/ARP Annual Meeting
Prevalence of Atopic Features in Classic Autoinflammatory Diseases
Brian Dizon¹, Hirsch komarow ¹, Deborah Stone ¹, Patrycja Hoffmann ¹, Anne Jones ¹, Tina Romeo ¹, Karyl Barron ¹, Ivona Aksentijevich ², Daniel Kastner ¹, Amanda Ombrello ¹, Joshua Milner ¹ and Daniella Schwartz ¹, ¹National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda
Background/Purpose: Autoinflammatory diseases (AIDs), often caused by single gene mutations, are disorders in which aberrant activation of innate immune cells causes uncontrolled systemic inflammation. Because…
Abstract Number: 947 • 2019 ACR/ARP Annual Meeting
TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2
Ryan Laird¹, Patrycja Hoffmann ², Karyl Barron ², Deborah Stone ², Michele Nehrebecky ³, Anne Jones ², Tina Romeo ², Camilo Toro ³, Arianne Soldatos ⁴, Cornelia Cudrici ³, Daniel Kastner ² and Amanda Ombrello ², ¹National Institues of Health, Bethesda, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, ⁴NIH/NINDS, Bethesda
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by biallelic loss-of-function mutations in the ADA2 gene . Over 60 pathogenic…
Abstract Number: 1244 • 2019 ACR/ARP Annual Meeting
Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children
Jasmin B. Kuemmerle-Deschner¹, Daniel Sturm ¹ and Susanne Benseler ², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Alberta Childrens Hospital Research Institute, Calgary, Canada
Background/Purpose: Evidence based treatment options for children and adults with unclassified autoinflammatory diseases (AID) are limited. Frequently, IL-1-inhibition is primarily tried to control the severe…
Abstract Number: 926 • 2018 ACR/ARHP Annual Meeting
Truncating Mutations in SAMD9L Cause an Early-Onset Immune-Dysregulatory Syndrome of Neutrophilic Panniculitis, Interstitial Lung Disease and Cytopenias
Adriana Almeida de Jesus¹, Bernadette Marrero¹, Gina A. Montealegre Sanchez¹, Jon (Sandy) Burnham², Alice Chan³, Yuriy Stepanovskiy⁴, Angela Rösen-Wolff⁵, Christian Hedrich⁶, MinAe Lee-Kirsch⁵, Joseph A. Duncan⁷, Jin Yao Mo⁷, Liliana Bezrodnik⁸, Gisela Seminario⁸, Maria Soledad Caldirola⁸, Eric Allenspach⁹, Troy R. Torgerson¹⁰, Laura Finn¹¹, Rachel VanTries¹, Yan Huang¹, Stephen R. Brooks¹², Zuoming Deng¹³ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatrics, UCSF, San Francisco, CA, ⁴Shupyk National Academy of Postgraduate Education, Kyiv, Ukraine, ⁵Children's Hospital Dresden, Dresden, Germany, ⁶Pediatric Rheumatology and Immunology, Children's Hospital Dresden, Dresden, Germany, ⁷University of North Carolina School of Medicine, Chapel Hill, NC, ⁸Center of Clinical Immunology, Buenos Aires, Argentina, ⁹Immunology/Rheumatology, Seattle Children's Research Institute, Seattle, WA, ¹⁰Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ¹¹University of Washington and Seattle Children's Hospital, Seattle, WA, ¹²Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ¹³NIAMS/NIH, Bethesda, MD
Background/Purpose: The Sterile Alpha Motif Domain Containing 9 Like protein that is encoded by SAMD9L plays a role in endosome fusion, and deletions (haploinsufficiency) of…
Abstract Number: 1321 • 2018 ACR/ARHP Annual Meeting
Clinical and Genetic Analysis of the Patients Mimicking Familial Mediterranean Fever
Dai Kishida¹, Yasuhiro Shimojima² and Yoshiki Sekijima¹, ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Clinical and genetic analysis of the patients mimicking familial Mediterranean feverBackground/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent episodes of fever…
Abstract Number: 1412 • 2018 ACR/ARHP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome
Jasmin B. Kuemmerle-Deschner¹, Raju Gautam², Aneesh Thomas George², Syed Raza², Kathleen Graham Lomax³ and Peter Hur³, ¹Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital, Tuebingen, Germany, Tuebingen, Germany, ²Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India, ³Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ
Background/Purpose: Hyperimmunoglobulinemia D syndrome (HIDS), also known as mevalonate kinase deficiency (MKD), and TNF receptor-associated periodic syndrome (TRAPS) are rare auto-inflammatory diseases grouped as periodic…
Abstract Number: 1415 • 2018 ACR/ARHP Annual Meeting
Emapalumab, an Anti-Interferon Gamma Monoclonal Antibody in Two Patients with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Claudia Bracaglia¹, Giusi Prencipe¹, Antonella Insalaco¹, Ivan Caiello², Giulia Marucci¹, Raffaele Pecoraro³, Manuela Pardeo¹, Pavla Dolezalova⁴, Sarka Fingerhutova⁴, Maria Ballabio⁵, Cristina de Min⁵ and Fabrizio De Benedetti⁶, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³Pediatric Department, La Sapienza University of Rome, Rome, Italy, ⁴Paediatric Rheumatology Unit, General University Hospital in Prague and 1st Faculty of Medicine, Charles University, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic, ⁵NovImmune S.A., Geneva, Switzerland, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Interferon gamma (IFNγ) plays a pathogenic role in primary and secondary HLH. An ongoing phase 2/3 trial with emapalumab in primary HLH provides encouraging…
Abstract Number: 1426 • 2018 ACR/ARHP Annual Meeting
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Najla Aljaberi¹, Angela Merritt², Alexei Grom¹, Grant Schulert³, Jennifer L. Huggins⁴, Michael Henrickson⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children’s Medical Center, Cincinnati, OH
Background/Purpose: S100 proteins are calcium-binding proteins of increasing value as biomarkers in various inflammatory conditions (e.g. autoinflammatory diseases, vasculitides, inflammatory bowel disease). The two highly…
Abstract Number: 1911 • 2018 ACR/ARHP Annual Meeting
The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Karyl Barron¹, Amanda Ombrello², Deborah Stone², Patrycja M. Hoffmann², Tina Romeo², Anne Jones³, Natalia Sampaio Moura², Oskar Schnappauf², Ivona Aksentijevich³, Jenna Bergerson¹, Ariane Soldatos⁴, Camilo Toro³, Theo Heller⁵, Jennifer Kanakry⁶, Katherine R Calvo⁷ and Daniel Kastner³, ¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²NHGRI, National Institutes of Health, Bethesda, MD, ³National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴NINDS, National Institutes of Health, Bethesda, MD, ⁵NIDDK, National Institutes of Health, Bethesda, MD, ⁶NCI, National Institutes of Health, Bethesda, MD, ⁷CC/DLM, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase 2 (DADA2) was initially described in 2014 in 2 reports: one emphasizing early-onset lacunar strokes, livedoid rash and intermittent…
Abstract Number: 2023 • 2018 ACR/ARHP Annual Meeting
Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases
Adriana Almeida de Jesus¹, Yanfeng Hou², Louise Malle³, Scott Canna⁴, Gina A. Montealegre Sanchez¹, Hanna Kim⁵, Rachel VanTries¹, Seza Ozen⁶, Samantha Dill⁷, Dawn C. Chapelle⁷, Bernadette Marrero¹, Yan Huang¹, Angelique Biancotto⁸ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Department of Rheumatology, Shandong Provincial Qianfoshan Hospital, Shandong University, Shandong, China, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴RK Mellon Institute for Pediatric Research, University of Pittsburgh/Children's Hospital of Pittsburgh of UPMC, Pittsburrgh, PA, ⁵Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ⁶Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁷Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ⁸Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD
Background/Purpose: Many infants and children with early-onset autoinflammatory diseases are mutation-negative for genetically known autoinflammatory diseases. Recent data suggest a role for Type-I interferon dysregulation…
Abstract Number: 2279 • 2018 ACR/ARHP Annual Meeting
Therapeutic Value of Canakinumab in Patients with Yao Syndrome
Qingping Yao, Rheumatology, Allergy and Immunology, Stony Brook University Hospital, Stony Brook, NY; Rheumatology, Allergy, and Immunology, Stony Brook University School of Medicine, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321), formerly termed nucleotide-binding, oligomerization domain 2(NOD2)-associated autoinflammatory disease, is characterized by periodic fever, dermatitis, arthritis, and swelling of the…
Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
Jasmin B. Kuemmerle-Deschner¹, Konstanze Hoertnagel², Susanne Schlipf³, Sandra Hansmann⁴, Toni Hospach⁵, Ilias Tsiflikas⁶, Xiao Liu⁷, Susanne Benseler⁸ and Alexander Weber⁷, ¹Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Praxis für Humangenetik Tübingen,Tuebingen, Germany, Tuebingen, Germany, ³Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd, Germany, Schwäbisch Gmünd, Germany, ⁴Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁶Division of Pediatric Radiology, Department of Radiology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ⁷Department of Immunology, University of Tübingen, Tübingen, Germany, Tuebingen, Germany, ⁸Rheumatology, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada, Calgary, AB, Canada
Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].